Danish and Swedish patients with RA: crude and age-adjusted and gender-adjusted IR of serious infections in 6-month intervals following start of treatment with abatacept, rituximab or tocilizumab
| Abatacept | Rituximab | Tocilizumab | ||||
| Serious infections, 0–6 months | ||||||
| Country | Denmark | Sweden | Denmark | Sweden | Denmark | Sweden |
| PY | 359 | 858 | 329 | 1202 | 507 | 818 |
| Infections, n | 34 | 51 | 38 | 99 | 35 | 42 |
| Crude IR/100 PY (95% CI) | 9.5 (6.8 to 13.3) | 5.9 (4.5 to 7.8) | 11.6 (8.4 to 15.9) | 8.2 (6.8 to 10.0) | 6.9 (5.0 to 9.6) | 5.1 (3.8 to 6.9) |
| Adjusted IR | 9.7 (6.8 to 13.8) | 5.9 (4.4 to 8.0) | 11.0 (7.8 to 15.6) | 7.5 (5.9 to 9.5) | 7.1 (5.0 to 10.0) | 5.5 (4.0 to 7.4) |
| Serious infections, 6–12 months | ||||||
| PY | 209 | 619 | 242 | 987 | 399 | 608 |
| Infections, n | 6 | 39 | 12 | 57 | 20 | 23 |
| Crude IR/100 PY (95% CI) | 2.9 (1.3 to 6.4) | 6.3 (4.6 to 8.6) | 5.0 (2.8 to 8.8) | 5.8 (4.5 to 7.5) | 5.0 (3.2 to 7.8) | 3.8 (2.5 to 5.7) |
| Adjusted IR* | 2.5 (1.1 to 5.7) | 5.9 (4.2 to 8.4) | 3.8 (2.0 to 7.0) | 5.0 (3.7 to 6.7) | 4.4 (2.7 to 7.0) | 3.8 (2.4 to 5.9) |
| Serious infections, 12–18 months | ||||||
| PY | 85 | 407 | 166 | 759 | 254 | 412 |
| Infections, n | 1 | 26 | 10 | 43 | 6 | 17 |
| Crude IR/100 PY (95% CI) | 1.2 (0.2 to 8.4) | 6.4 (4.3 to 9.4) | 6.0 (3.2 to 11.2) | 5.7 (4.2 to 7.6) | 2.4 (1.1 to 5.3) | 4.1 (2.6 to 6.6) |
| Adjusted IR* | 1.0 (0.1 to 7.3) | 5.8 (3.9 to 8.6) | 4.6 (2.2 to 9.5) | 4.5 (3.1 to 6.7) | 2.1 (1.1 to 4.9) | 4.1 (2.5 to 6.7) |
| Serious infections, 18–24 months | ||||||
| PY | 59 | 299 | 133 | 632 | 205 | 323 |
| Infections, n | 1 | 11 | 9 | 42 | 9 | 8 |
| Crude IR/100 PY (95% CI) | 1.7 (0.2 to 12) | 3.7 (2.0 to 6.6) | 6.8 (3.5 to 13.1) | 6.6 (4.9 to 9.0) | 4.4 (2.3 to 8.4) | 2.5 (1.2 to 4.9) |
| Adjusted IR* | 1.7 (0.2 to 12) | 3.1 (1.6 to 5.8) | 6.7 (3.5 to 12) | 5.2 (3.5 to 7.8) | 4.2 (2.2 to 8.2) | 2.2 (1.1 to 4.6) |
*Adjusted for age and gender.
IR, incidence rate; PY, person years; RA, rheumatoid arthritis.